The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: